Results 61 to 70 of about 13,529 (168)

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. [PDF]

PLoS ONE, 2011
In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit over placebo in the primary endpoint of coronary heart disease events. Increased levels of atherogenic homocysteine were observed in some patients assigned
Laxman Yetukuri, Ilkka Huopaniemi, Artturi Koivuniemi, Marianna Maranghi, Anne Hiukka, Heli Nygren, Samuel Kaski, Marja-Riitta Taskinen, Ilpo Vattulainen, Matti Jauhiainen, Matej Orešič   +10 more
doaj   +1 more source

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

British Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra, Francesco Niro, Marco Mergiotti, Giovanni Gavatorta, Emilio Hirsch, Alessandra Ghigo   +5 more
wiley   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα -mediated inhibition of Glioma cell motility in vitro

Molecular Cancer, 2010
Background Glioblastomas are characterized by rapid cell growth, aggressive CNS infiltration, and are resistant to all known anticancer regimens. Recent studies indicate that fibrates and statins possess anticancer potential.
Del Valle Luis, Wybieralska Ewa, Grabacka Maja, Wilk Anna, Urbanska Katarzyna, Drukala Justyna, Madeja Zbigniew, Reiss Krzysztof   +7 more
doaj   +1 more source

Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis

Hepatology Research, EarlyView.
Pemafibrate improves liver function markers related to bile flow in primary biliary cholangitis (PBC), but whether this effect is disease‐specific remains unclear. In this study, pemafibrate reduced these markers in patients with and without PBC, suggesting broader effects on bile flow beyond PBC.
Ryohei Tanigawa, Yoshiyuki Ueno, Hirokazu Takahashi, Ayumi Saito, Hideki Suganami, Atsushi Tanaka   +5 more
wiley   +1 more source

Fenofibrate Inhibited the Differentiation of T Helper 17 Cells In Vitro

PPAR Research, 2012
Uncontrolled activity of T cells mediates autoimmune and inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, rheumatoid arthritis, type 1 diabetes, and atherosclerosis.
Zhou Zhou, Weiliang Sun, Ying Liang, Yanxiang Gao, Wei Kong, Youfei Guan, Juan Feng, Xian Wang   +7 more
doaj   +1 more source

Online tool for refining socio‐economic analyses better than postcodes: the example of cardiovascular disease in type 2 diabetes in the FIELD trial

Internal Medicine Journal, EarlyView.
Abstract Background Socio‐economic status (SES) is strongly linked to health outcomes but remains difficult to measure accurately. Conventional approaches based on large geographical units (e.g. postcodes) may obscure SES effects evident at smaller scales.
Andrzej S. Januszewski, Liping Li, Rachel L. O'Connell, James D. Best, R. John Simes, David R. Sullivan, Timothy M. E. Davis, Anthony C. Keech, on behalf of FIELD Trial Investigators   +8 more
wiley   +1 more source

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 9, Page 1288-1297, November 2026.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean, Maryam Yazdanfar, Joseph Zepeda, Isha J. Patel, Cynthia Levy, Craig Lammert, Raghav Bordia, Duru Cosar, Katherine Specht, Daniel Pratt, Stuart C. Gordon, Lisa Forman, Fawzy Barry, Michael Li, Usha Gungabissoon, Megan M. McLaughlin, Christopher L. Bowlus   +16 more
wiley   +1 more source